NVO - NOVO NORDISK A S

QQQ $ 446.25 $ -12.35 (-2.68 %)

DIA $ 404.28 $ -3.99 (-0.98 %)

SPY $ 539.90 $ -9.25 (-1.68 %)

TLT $ 99.49 $ -0.01 (-0.01 %)

GLD $ 230.65 $ -1.72 (-0.74 %)

Previous Close

$ 131.14

Open

$ 134.16

Bid

$ 131.18 x 100

Ask

-- x --

Day's Range

$ 130.57 - $ 134.16

52 Week Range

$ 86.02 - $ 147.60

Volume

2,591,817

Average Volume

Market Cap

591,441

Beta (5Y Monthly)

$ 0.67

PE Ratio (TTM)

$ 0.00

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.01)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type	Report Link
No Data found

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

what-the-options-market-tells-us-about-novo-nordisk

What the Options Market Tells Us About Nov...
09/06/2024 16:16:15

goldman-sachs-shifts-stance-on-novartis-cites-lack-of-near-term-catalysts

Goldman Sachs Shifts Stance On Novartis, C...
09/05/2024 18:34:15

Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential.

fake-ozempic-targets-weight-loss-market-forged-batches-an-international-concern

Fake Ozempic Targets Weight-Loss Market: F...
09/05/2024 17:17:20

Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation...

battle-over-compounded-weight-loss-medications---sustainability-and-regulation

Battle Over Compounded Weight-Loss Medicat...
09/05/2024 16:47:47

Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing ...

Novo Nordisk Unusual Options Activity
09/05/2024 15:32:05

ascendis-pharma-faces-challenges-with-skytrofa-and-yorvipath-pricing-analysts-weigh-in

Ascendis Pharma Faces Challenges With Skyt...
09/04/2024 21:02:35

Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included...

bioage-labs-files-for-100m-ipo-becomes-the-new-entrant-in-obesity-drugs-race

BioAge Labs Files For $100M IPO, Becomes T...
09/04/2024 15:13:09

BioAge Labs a biotech company focused on therapies for metabolic diseases, has filed for a $100 million IPO. Founded in 2015, t...

MHRA Finds No Evidence Supporting Link Bet...
09/04/2024 14:52:07

- Reuters

despite-medicare-negotiations-americans-may-still-have-to-pay-more-for-prescription-drugs

Despite Medicare Negotiations, Americans M...
09/03/2024 19:12:09

Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly hig...

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
09/03/2024 17:35:17

eli-lilly-launches-discounted-mounjaro-and-zepbound-as-fight-against-compounded-imitations-escalates-amid-ongoing-fda-shortage-status-debate

Eli Lilly Launches Discounted Mounjaro And...
09/02/2024 07:43:18

Eli Lilly is intensifying its efforts to combat imitation versions of its popular appetite-suppressing drugs, Mounjaro and Zepb...

ozempic-unexpected-anti-aging-miracle-drug-researchers-reveal-surprising-potential

Ozempic: Unexpected Anti-Aging Miracle Dru...
08/31/2024 19:30:16

Ozempic may offer unexpected anti-aging benefits, potentially improving health and reducing mortality rates, according to new r...

judges-early-ruling-may-shape-outcome-in-ozempic-wegovy-lawsuits

Judge's Early Ruling May Shape Outcome In ...
08/30/2024 17:38:20

A Philadelphia judge's early ruling in the Ozempic and Wegovy litigation may shape the outcome of the lawsuits against Novo...

novo-nordisk-touts-encouraging-wegovy-data-to-lower-risk-of-severe-complications-in-heart-failure-patients

Novo Nordisk Touts Encouraging Wegovy Data...
08/30/2024 13:54:13

Novo Nordisk's semaglutide reduced the risk of cardiovascular events in heart failure patients by 31% in recent trials publ...

Novo Nordisk Says New Pooled Analysis Publ...
08/30/2024 11:41:02

eli-lilly-is-the-nvidia-of-weight-loss-and-glp-1-space-says-roundhill-investments-ceo-emphasizes-market-leadership-and-growth-potential-of-zepbound-maker

Eli Lilly Is The Nvidia Of Weight Loss And...
08/28/2024 08:21:26

Roundhill Investments CEO Dave Mazza compared Eli Lilly And Co to Nvidia in the weight loss and GLP-1 space.

looking-at-novo-nordisks-recent-unusual-options-activity

Looking At Novo Nordisk's Recent Unusual O...
08/27/2024 19:01:51

governments-suing-pharmacy-benefit-managers-over-insulin-prices-have-long-benefited-from-their-rebates

Governments Suing Pharmacy Benefit Manager...
08/26/2024 17:59:43

State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system t...

novo-nordisk-does-not-operate-as-drug-cartel-ceo-defends-us-pricing-of-ozempic-against-criticism-over-high-drug-prices

Novo Nordisk Does Not Operate As Drug Cart...
08/26/2024 12:39:51

Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senat...

novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets

Novo Nordisk's Ozempic Might Be Among 2027...
08/23/2024 18:21:18

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...